54998-08-2

Basic information

• Product Name: 4-(4-Methylpiperazino)-1,2-benzenediamine
• Synonyms: 4-(4-Methylpiperazino)-1,2-benzenediamine-8;4-(4-Methylpiperazino)-1,2-benzenediamine 4HCl;4-(4-methyl-piperazin-1-yl)-2-amino-aniline;1,2-Benzenediamine,4-(4-methyl-1-piperazinyl)-;4-(4-METHYLPIPERAZINO)-1,2-BENZENEDIAMINE;4-(4-methylpiperazin-1-yl)benzene-1,2-diamine
• CAS NO: 54998-08-2
• Molecular Formula: C₁₁H₁₈N₄
• Molecular Weight: 206.29
• Mol File: 54998-08-2.mol
• Article Data: 59

Chemical Properties

• Melting Point: 118-120°C
• Boiling Point: 419.7 °C at 760 mmHg
• Flash Point: 258.7 °C
• Appearance: /
• Density: 1.163 g/cm³
• Vapor Pressure: 2.97E-07mmHg at 25°C
• Refractive Index: 1.631
• PKA: 7.84±0.42(Predicted)
• CAS DataBase Reference: 4-(4-Methylpiperazino)-1,2-benzenediamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Methylpiperazino)-1,2-benzenediamine(54998-08-2)
• EPA Substance Registry System: 4-(4-Methylpiperazino)-1,2-benzenediamine(54998-08-2)

Safety Data

• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36/37/39-24/25
• HazardClass: IRRITANT
• Hazardous Substances Data: 54998-08-2(Hazardous Substances Data)

Usage

Chemical Properties

Solid

InChI:InChI=1/C11H18N4/c1-14-4-6-15(7-5-14)9-2-3-10(12)11(13)8-9/h2-3,8H,4-7,12-13H2,1H3

Upstream product

• 364-53-4 4-fluoro-1,2-dinitro-benzene 
• 109-01-3 1-methyl-piperazine 
• 1635-61-6 5-chloro-2-nitroaniline 
• 95-83-0 4-Chloro-1,2-phenylenediamine 
• 23491-48-7 5-(4-methylpiperazine-1-yl)-2-nitroaniline 

Downstream Products

• 129012-02-8 2-(4-Methoxy-phenyl)-6-[6-(4-methyl-piperazin-1-yl)-1H-benzoimidazol-2-yl]-benzooxazole 
• 120423-35-0 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-5⁽⁶⁾-(4-methyl-1-piperazinyl)benzimidazole 
• 129244-58-2 2-(3,5-di-tert-butyl-4-hydroxybenzyl)-5⁽⁶⁾-(4-methyl-1-piperazinyl)benzimidazole 
• 129244-61-7 2-(3,5-di-tert-butyl-4-hydroxyphenethyl)-5⁽⁶⁾-(4-methyl-1-piperazinyl)benzimidazole 
• 129244-66-2 2-<2-(3,5-di-tert-butyl-4-hydroxyphenyl)-5'(6')-benzimidazolyl>-5(6)-<1-(4-methylpiperazinyl)>benzimidazole 
• 129244-67-3 2-<2-(3,5-di-tert-butyl-4-hydroxybenzyl)-5'(6')-benzimidazolyl>-5(6)-<1-(4-methylpiperazinyl)>benzimidazole 
• 129244-68-4 2-<2-(3,5-di-tert-butyl-4-hydroxyphenethyl)-5'(6')-benzimidazolyl>-5(6)-<1-(4-methylpiperazinyl)>benzimidazole 
• 23623-05-4 4-<5'-(4''-methylpiperazin-1''-yl)benzimidazol-2'-yl>-2-nitroaniline 
• 23623-08-7 2'-phenyl-5-(4-methylpiperazinyl)-2,5'-bi-1H-benzimidazole 
• 23491-54-5 2'-m-tolyl-5-(4-methylpiperazinyl)-2,5'-bi-1H-benzimidazole 
• 23554-98-5 2'-(4-hydroxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-1H-benzimidazole 
• 23491-55-6 2'-(naphth-2-yl)-5-(4-methylpiperazinyl)-2,5'-bi-1H-benzimidazole 
• 23491-52-3 2-[2-(4-ethoxyphenyl)benzimidazol-5⁽⁶⁾-yl]-5⁽⁶⁾-(4-methylpiperazin-1-yl)benzimidazole 
• 23491-49-8 2-amino-4-<5'-(4''-methylpiperazin-1''-yl)benzimidazol-2'-yl>aniline 

Relevant articles and documents

Kinetic Target-Guided Synthesis of Small-Molecule G-Quadruplex Stabilizers

The formation of a G-quadruplex motif in the promoter region of the c-MYC protooncogene prevents its expression. Accordingly, G-quadruplex stabilization by a suitable ligand may be a viable approach for anticancer therapy. In our study, we used the 4-(4-m

Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy

As epigenetic readers, bromodomain and extra-terminal domain (BET) family proteins bind to acetylated-lysine residues in histones and recruit protein complexes to promote transcription initiation and elongation. Inhibition of BET bromodomains by small molecule inhibitors has emerged as a promising therapeutic strategy for cancer. Herein, we describe our efforts toward the discovery of a novel series of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as BET inhibitors. Intensive structural modifications led to the identification of compound 35f as the most active inhibitor of BET BRD4 with selectivity against BET family proteins. Further biological studies revealed that compound 35f can arrest the cell cycle in G0/G1 phase and induce apoptosis via decreasing the expression of c-Myc and other proteins related to cell cycle and apoptosis. More importantly, compound 35f showed favorable pharmacokinetic properties and antitumor efficacy in MV4-11 mouse xenograft model with acceptable tolerability. These results indicated that BET inhibitors could be potentially used to treat hematologic malignancies and some solid tumors.

Benzimidazole compound, preparation method thereof and application of the benzimidazole compound in preparation of ferroptosis inhibitor

The invention discloses a benzimidazole compound, a preparation method thereof and application of the benzimidazole compound in preparation of a ferroptosis inhibitor. The benzimidazole compound has a structure as shown in a formula (I) or a formula (II)